STOCK TITAN

Mallinckrodt to Report Earnings Results for Fourth Quarter 2022

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary

Mallinckrodt plc (NYSE American: MNK) announced it will report its fourth quarter 2022 earnings on February 28, 2023. The reporting period ends on December 30, 2022.

The company also plans a conference call for investors at 8:30 a.m. ET on the same day. This call will allow stakeholders to engage with the company's financial results.

Mallinckrodt specializes in pharmaceutical products, focusing on areas such as autoimmune and rare diseases.

Positive
  • Scheduled earnings report may provide insights into financial performance and investor expectations.
  • Potential opportunity for investor engagement through the conference call.
Negative
  • No specific financial metrics or guidance provided, which could affect investor sentiment.

DUBLIN, Feb. 8, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE American: MNK), a global specialty pharmaceutical company, today announced that it will report fourth quarter 2022 earnings results for the period ended December 30, 2022, on Tuesday, February 28, 2023

A conference call for investors will begin at 8:30 a.m. ET. The call can be accessed as follows:

ABOUT MALLINCKRODT 
Mallinckrodt is a global business consisting of multiple wholly owned subsidiaries that develop, manufacture, market and distribute specialty pharmaceutical products and therapies. The Company's Specialty Brands reportable segment's areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, hepatology, nephrology, pulmonology, ophthalmology and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; cultured skin substitutes and gastrointestinal products. Its Specialty Generics reportable segment includes specialty generic drugs and active pharmaceutical ingredients. To learn more about Mallinckrodt, visit www.mallinckrodt.com.

Mallinckrodt uses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information. It also uses its website to expedite public access to time-critical information regarding the Company in advance of or in lieu of distributing a press release or a filing with the U.S. Securities and Exchange Commission (SEC) disclosing the same information. Therefore, investors should look to the Investor Relations page of the website for important and time-critical information. Visitors to the website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations page of the website.

CONTACTS

Investor Relations
Daniel Speciale
Global Corporate Controller & Chief Investor Relations Officer
314-654-3638
daniel.speciale@mnk.com

Derek Belz
Vice President, Investor Relations
314-654-3950
derek.belz@mnk.com

Media
Michael Freitag / Aaron Palash / Aura Reinhard
Joele Frank, Wilkinson Brimmer Katcher
212-355-4449

Mallinckrodt, the "M" brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company. © 2023 02/23.

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/mallinckrodt-to-report-earnings-results-for-fourth-quarter-2022-301741804.html

SOURCE Mallinckrodt plc

FAQ

When will Mallinckrodt report its fourth quarter 2022 earnings?

Mallinckrodt will report its fourth quarter 2022 earnings on February 28, 2023.

What time is Mallinckrodt's investor conference call?

The investor conference call will take place at 8:30 a.m. ET on February 28, 2023.

What is the significance of Mallinckrodt's fourth quarter earnings report?

The fourth quarter earnings report will provide insights into the company's financial performance for the period ending December 30, 2022.

Where can I access the earnings report and conference call details for Mallinckrodt?

Details for the earnings report and conference call can be accessed on Mallinckrodt's Investor Relations page.

Mallinckrodt plc

NYSE:MNK

MNK Rankings

MNK Latest News

MNK Stock Data

4.52M
5.72M
10.09%
96.64%
13.46%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
Ireland
Dublin